Arvind R Murali1, Subhash Chandra, Zoe Stewart, Bruce R Blazar, Umar Farooq, M Nedim Ince, Jeffrey Dunkelberg. 1. 1 Department of Internal Medicine, Division of Gastroenterology & Hepatology, University of Iowa Hospitals and Clinics, Iowa City, IA.2 Department of Surgery, Division of Transplantation & Hepatobiliary Surgery, University of Iowa Hospitals and Clinics, Iowa City, IA.3 Department of Pediatrics, Division of Blood and Bone Marrow Transplantation, University of Minnesota, Minneapolis, MN.4 Department of Internal Medicine, Division of Hematology and Oncology, Bone Marrow Transplant, University of Iowa Hospitals and Clinics, Iowa City, IA.
Abstract
BACKGROUND: Graft-versus-host-disease (GVHD) after liver transplantation (LT) is a deadly complication with very limited data on risk factors, diagnosis and management. We report a case series and a comprehensive review of the literature. METHODS: Data were systematically extracted from reports of GVHD after LT, and from the United Network for Organ Sharing database. Group comparisons were performed. RESULTS: One hundred fifty-six adult patients with GVHD after LT have been reported. Median time to GVHD onset was 28 days. Clinical features were skin rash (92%), pancytopenia (78%), and diarrhea (65%). Six-month mortality with GVHD after LT was 73%. Sepsis was the most common cause of death (60%). Enterobacter bacteremia, invasive aspergillosis, and disseminated Candida infections were frequently reported. Recipient age over 50 years is a risk factor for GVHD after LT. Hepatocellular carcinoma was overrepresented, whereas chronic hepatitis C was underrepresented, in reported United States GVHD cases relative to all United Network for Organ Sharing database LT cases. Mortality rate with treatment of GVHD after LT was 84% with high-dose steroids alone, 75% to 100% with regimens using dose increases of calcineurin inhibitors, and 55% with IL-2 antagonists. Mortality was 25% in small case series using the CD2-blocker alefacept or TNF-α antagonists. CONCLUSIONS: Age older than 50 years and hepatocellular carcinoma appear to be risk factors for GVHD. Hepatitis C may be protective. High-dose steroids and calcineurin inhibitors are ineffective in the treatment of GVHD after LT. CD2-blockers and TNF-α antagonists appear promising. We propose a diagnostic algorithm to assist clinicians in managing adults with GVHD after LT.
BACKGROUND:Graft-versus-host-disease (GVHD) after liver transplantation (LT) is a deadly complication with very limited data on risk factors, diagnosis and management. We report a case series and a comprehensive review of the literature. METHODS: Data were systematically extracted from reports of GVHD after LT, and from the United Network for Organ Sharing database. Group comparisons were performed. RESULTS: One hundred fifty-six adult patients with GVHD after LT have been reported. Median time to GVHD onset was 28 days. Clinical features were skin rash (92%), pancytopenia (78%), and diarrhea (65%). Six-month mortality with GVHD after LT was 73%. Sepsis was the most common cause of death (60%). Enterobacter bacteremia, invasive aspergillosis, and disseminated Candida infections were frequently reported. Recipient age over 50 years is a risk factor for GVHD after LT. Hepatocellular carcinoma was overrepresented, whereas chronic hepatitis C was underrepresented, in reported United States GVHD cases relative to all United Network for Organ Sharing database LT cases. Mortality rate with treatment of GVHD after LT was 84% with high-dose steroids alone, 75% to 100% with regimens using dose increases of calcineurin inhibitors, and 55% with IL-2 antagonists. Mortality was 25% in small case series using the CD2-blocker alefacept or TNF-α antagonists. CONCLUSIONS: Age older than 50 years and hepatocellular carcinoma appear to be risk factors for GVHD. Hepatitis C may be protective. High-dose steroids and calcineurin inhibitors are ineffective in the treatment of GVHD after LT. CD2-blockers and TNF-α antagonists appear promising. We propose a diagnostic algorithm to assist clinicians in managing adults with GVHD after LT.
Authors: F Lehner; T Becker; L Sybrecht; R Lück; R Schwinzer; K Slateva; R Blasczyk; B Hertenstein; J Klempnauer; B Nashan Journal: Transplantation Date: 2002-01-27 Impact factor: 4.939
Authors: U P Neumann; U Kaisers; J M Langrehr; A R Müller; G Blumhardt; W O Bechstein; H Lobeck; H Riess; R Zimmermann; P Neuhaus Journal: Transplant Proc Date: 1994-12 Impact factor: 1.066
Authors: Joseph P Uberti; Lois Ayash; Voravit Ratanatharathorn; Samuel Silver; Christopher Reynolds; Michael Becker; Pavan Reddy; Kenneth R Cooke; Gregory Yanik; Joel Whitfield; Dawn Jones; Raymond Hutchinson; Thomas Braun; James L M Ferrara; John E Levine Journal: Biol Blood Marrow Transplant Date: 2005-09 Impact factor: 5.742
Authors: P Jeanmonod; M Hubbuch; F Grünhage; A Meiser; K Rass; M K Schilling; O Kollmar Journal: Transpl Infect Dis Date: 2012-06-01 Impact factor: 2.228
Authors: Edie Y Chan; Anne M Larson; Terry B Gernsheimer; Kris V Kowdley; Robert L Carithers; Jorge D Reyes; James D Perkins Journal: Liver Transpl Date: 2007-04 Impact factor: 5.799
Authors: Sven Kohler; Andreas Pascher; Guido Junge; Igor M Sauer; Marion Nagy; Constanze Schönemann; Martin Koch; Ulf Neumann; Johann Pratschke; Peter Neuhaus Journal: Transpl Int Date: 2008-02-04 Impact factor: 3.782
Authors: Jason P Cooper; James D Perkins; Paul R Warner; Alexandra Shingina; Scott W Biggins; Janis L Abkowitz; Jorge D Reyes Journal: Liver Transpl Date: 2021-11-05 Impact factor: 6.112
Authors: Mark E Snyder; Michael O Finlayson; Thomas J Connors; Pranay Dogra; Takashi Senda; Erin Bush; Dustin Carpenter; Charles Marboe; Luke Benvenuto; Lori Shah; Hilary Robbins; Jaime L Hook; Megan Sykes; Frank D'Ovidio; Matthew Bacchetta; Joshua R Sonett; David J Lederer; Selim Arcasoy; Peter A Sims; Donna L Farber Journal: Sci Immunol Date: 2019-03-08